Navigation Links
BioSpecifics Technologies Corp. to Present at Jefferies 2013 Global Healthcare Conference
Date:5/28/2013

LYNBROOK, N.Y., May 28, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in-class collagenase-based products marketed as XIAFLEX® in the U.S., today announced that BioSpecifics' President, Tom Wegman , will present a corporate overview at the upcoming Jefferies 2013 Global Healthcare Conference at 10:00 a.m. EDT on Monday, June 3, 2013 in New York, NY. 

The live webcast of this presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com or at the link http://wsw.com/webcast/jeff77/bstc/.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord in the palm by BioSpecifics' partner, Auxilium Pharmaceuticals, Inc., and is approved for Dupuytren's contracture in the EU and Canada. XIAFLEX is also in clinical development for the treatment of several additional promising indications. The U.S. Food & Drug Administration has accepted for filing Auxilium's supplemental Biologics License Application for XIAFLEX for the potential treatment of Peyronie's disease. The FDA is expected to take action on the application by September 6, 2013, and, if approved, XIAFLEX will be the first and only biologic treatment indicated for Peyronie's disease. Auxilium is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite. Auxilium has reported positive top-line data from a Phase IIa frozen shoulder study and expects to initiate a new clinical trial in the second half of 2013. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human and canine lipomas, which are both in Phase II clinical trials, with top-line data from both trials expected in the second half of 2013. Auxilium is currently partnered with Asahi Kasei Pharma Corporation for the development and commercialization of XIAFLEX for Dupuytren's contracture and Peyronie's disease in Japan and with Actelion Pharmaceuticals Ltd. for these same indications in Canada, Australia, Brazil and Mexico. For more information, please visit www.biospecifics.com.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
4. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
6. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
7. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
9. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
10. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
11. West Physics Consulting Teams with Mirion Technologies Dosimetry Services Division to Deliver Radiation Detection Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2020)... , ... July 07, 2020 , ... ... 2017, the company began as a hair service provider. Now called Bright, the ... work-from-home employees. Bright’s expanded offering includes beauty amenities as well as an array ...
(Date:7/4/2020)... ... July 03, 2020 , ... By Heidi Jean Doerfert , ... into our homes for cover, Assuaged, Inc. is going full speed ahead. ... the globe this year to get their feet wet in marketing, social media content, ...
(Date:7/2/2020)... TAMPA, Fla. (PRWEB) , ... July 02, 2020 , ... ... and fitness professionals, announced that 913,628,072 lifted pounds were logged through its software during ... training in this new age of fitness – an age where even gym giants ...
Breaking Medicine Technology:
(Date:7/22/2020)... ... July 22, 2020 , ... ... diseases for patients and staff. These measures include partnering with industry infectious ... This timely response is based on guidance from the Centers for Disease ...
(Date:7/18/2020)... ... 17, 2020 , ... With government legislation stating that hospitality and retail businesses ... either a mask or visor, there has been a drastic increase in demand for ... led to a spike in single-use plastic products being produced. , Due to ...
(Date:7/10/2020)... ... July 10, 2020 , ... Circularity ... with Circularity Healthcare’s mission to provide real and affordable healthcare solutions , ... prevent future pandemics by ending the commercial trade in wild animals, expanding wild ...
(Date:7/10/2020)... ... July 09, 2020 , ... NeoTract, a wholly owned subsidiary ... urology, today announced that Miguel Mercado, M.D., Texas Urology Specialists in Tomball, TX, ... Dr. Mercado has achieved a high level of training and experience with the ...
(Date:7/7/2020)... ... July 07, 2020 , ... Mediaplanet recently launched an ... The COVID-19 pandemic thrust this field into the spotlight and, as a result, ... careers by 2026. In partnership with South University — which offers a ...
Breaking Medicine News(10 mins):